Amanda Eymard, APRN
Psychiatric/Mental Health · Houma, LANPI 1790162626
Payments from drug & device makers
Across 1,415 payments — averaging $435.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$181K
- Alkermes, Inc.$155K
- Axsome Therapeutics, Inc.$121K
- Otsuka America Pharmaceutical, Inc.$115K
- AbbVie$21K
- Teva Pharmaceuticals USA, Inc.$20K
- plus $4K from 19 others
What the payments were for
- Consulting fees$109,46918%
- Speaking & faculty fees$428,28669%
- Travel & lodging$50,0258%
- Food & beverage$28,5875%
- Education$4720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 260 | $181,436 |
| Alkermes, Inc. | 395 | $155,117 |
| Axsome Therapeutics, Inc. | 210 | $120,633 |
| Otsuka America Pharmaceutical, Inc. | 264 | $115,375 |
| AbbVie | 90 | $20,665 |
| Teva Pharmaceuticals USA, Inc. | 59 | $20,064 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $1,277 |
| Vanda Pharmaceuticals Inc. | 14 | $414 |
| Johnson & Johnson | 16 | $395 |
| Indivior Inc. | 15 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $256 |
| E.r. Squibb & Sons, L.L.C. | 10 | $183 |
| Janssen Scientific Affairs, LLC | 1 | $143 |
| Lundbeck LLC | 8 | $133 |
| Idorsia Pharmaceuticals US Inc | 2 | $131 |
| Corium, LLC | 8 | $107 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Almatica Pharma LLC | 2 | $35 |
| Eisai Inc. | 2 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $19 |
| Bioxcel Therapeutics, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$356,395
- ARISTADA$237,308
- INGREZZA$176,931
- Auvelity$118,040
- REXULTI$77,609
- ARISTADA INITIO$53,460
- ABILIFY MAINTENA$32,801
- VRAYLAR$19,175
- UZEDY$18,850
- ABILIFY ASIMTUFII$11,285
- CAPLYTA$729
- INVEGA SUSTENNA$143
- COBENFY$122
- QUVIVIQ$118
How this compares
$616,838 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 82 | $668,971 |
| Invega SustennaPaliperidone Palmitate | 153 | $419,713 |
| VraylarCariprazine Hcl | 205 | $282,859 |
| AristadaAripiprazole Lauroxil | 94 | $280,575 |
| Invega TrinzaPaliperidone Palmitate | 26 | $229,146 |
| CaplytaLumateperone Tosylate | 53 | $93,172 |
| LybalviOlanzapine/Samidorphan Malate | 51 | $84,508 |
| TrintellixVortioxetine Hydrobromide | 122 | $66,256 |
| AuvelityDextromethorphan Hbr/Bupropion | 52 | $62,169 |
| RexultiBrexpiprazole | 40 | $47,433 |
| Abilify MaintenaAripiprazole | 16 | $42,321 |
| PerserisRisperidone | 11 | $29,977 |
| QuviviqDaridorexant Hcl | 19 | $9,793 |
| Aripiprazole | 203 | $9,076 |
| Oxcarbazepine | 211 | $8,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $181,436 | $668,97182 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $395 | $648,859179 claims |
| Alkermes, Inc.Aristada, Lybalvi | $155,117 | $365,083145 claims |
| AbbVieVraylar | $20,665 | $282,859205 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,277 | $93,17253 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $115,375 | $89,75456 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $256 | $71,280135 claims |
| Axsome Therapeutics, Inc.Auvelity | $120,633 | $62,16952 claims |
| Indivior Inc.Perseris | $280 | $29,97711 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $131 | $9,79319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Houma
- Timothy PellegrinHouma$210K
- Harry BrownHouma$9K
- Amy LacoutureBaton Rouge$663K
- Amber LittlefieldBroussard$225K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
- Michelle DyerLake Charles$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.